Generic Parsabiv Availability
Last updated on Apr 10, 2025.
Parsabiv is a brand name of etelcalcetide, approved by the FDA in the following formulation(s):
PARSABIV (etelcalcetide - solution;intravenous)
-
Manufacturer: KAI PHARMS INC
Approval date: February 7, 2017
Strength(s): 2.5MG/0.5ML (2.5MG/0.5ML) [RLD], 5MG/ML (5MG/ML) [RLD], 10MG/2ML (5MG/ML) [RLD]
Is there a generic version of Parsabiv available?
No. There is currently no therapeutically equivalent version of Parsabiv available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Parsabiv. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Stable liquid formulation of AMG 416 (etelcalcetide)
Patent 10,344,765
Issued: July 9, 2019
Inventor(s): Maclean Derek & Yin Qun
Assignee(s): Amgen Inc.A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
Patent expiration dates:
- June 27, 2034✓
- June 27, 2034
-
Stable liquid formulation of AMG 416 (etelcalcetide)
Patent 11,162,500
Issued: November 2, 2021
Inventor(s): Maclean Derek & Yin Qun
Assignee(s): Amgen Inc.A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
Patent expiration dates:
- June 27, 2034✓
- June 27, 2034
-
Stable liquid formulation of AMG 416 (etelcalcetide)
Patent 11,959,486
Issued: April 16, 2024
Inventor(s): Maclean; Derek et al.
Assignee(s): Amgen Inc. (Thousand Oaks, CA)A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
Patent expiration dates:
- June 27, 2034✓✓
- June 27, 2034
-
Therapeutic agents for reducing parathyroid hormone levels
Patent 8,377,880
Issued: February 19, 2013
Inventor(s): Karim Felix & Baruch Amos & MacLean Derek & Das Kanad & Yin Qun
Assignee(s): KAI Pharmaceuticals, Inc.Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X—X—X—X—X—X—X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X—Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
Patent expiration dates:
- July 29, 2030✓✓
- July 29, 2030
-
Therapeutic agents for reducing parathyroid hormone levels
Patent 8,999,932
Issued: April 7, 2015
Inventor(s): Karim Felix & Baruch Amos & Maclean Derek & Das Kanad & Yin Qun
Assignee(s): KAI Pharmaceuticals, Inc.Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X-X-X-X-X-X-X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
Patent expiration dates:
- February 7, 2031✓✓✓
- February 7, 2031
-
Therapeutic agents for reducing parathyroid hormone levels
Patent 9,278,995
Issued: March 8, 2016
Inventor(s): Karim Felix & Baruch Amos & Maclean Derek & Das Kanad & Yin Qun
Assignee(s): KAI PHARMACEUTICALS, INC.Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X-X-X-X-X-X-X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
Patent expiration dates:
- July 29, 2030✓
- July 29, 2030
-
Therapeutic agents for reducing parathyroid hormone levels
Patent 9,701,712
Issued: July 11, 2017
Inventor(s): Karim Felix & Baruch Amos & Maclean Derek & Das Kanad & Yin Qun
Assignee(s): KAI Pharmaceuticals, Inc.Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X—X—X—X—X—X—X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
Patent expiration dates:
- July 29, 2030✓✓✓
- July 29, 2030
-
Stable liquid formulation of AMG 416 (etelcalcetide)
Patent 9,820,938
Issued: November 21, 2017
Inventor(s): Maclean Derek & Yin Qun
Assignee(s): Amgen Inc.A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
Patent expiration dates:
- June 27, 2034✓
- June 27, 2034
More about Parsabiv (etelcalcetide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: calcimimetics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.